Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Operating Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	-20.22	-7.79	-9.57	-12.85	-42.43	-9.82
Depreciation & Amortization	0.01	0.01	0.01	0.01	0.12	-
Loss (Gain) From Sale of Assets	-	-	0	-0.02	0.4	-
Asset Writedown & Restructuring Costs	13.53	-	-	-	33.55	0.25
Stock-Based Compensation	0.6	0.8	0.73	0.91	1.81	1.34
Other Operating Activities	-3.09	-2.6	-6.42	0.9	-9.55	-6.22
Change in Accounts Receivable	-	0.11	0.6	0.08	-0.3	-0.02
Change in Accounts Payable	-1.07	0.54	-0.08	-1.65	0.41	-2.39
Change in Other Net Operating Assets	-0.06	0.07	-0.17	0.29	0.07	-0.38
Operating Cash Flow	-10.29	-8.87	-14.9	-12.33	-15.91	-17.23
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-	-	-	-0.02	-0.02	-
Sale of Property, Plant & Equipment	-	-	-	0.11	-	-
Investment in Securities	-	-	-	0.02	13.17	-3.52
Investing Cash Flow	-	-	-	0.1	13.15	-3.52

Financing Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Issuance of Common Stock	4.04	4.04	15	7.52	0.3	-
Other Financing Activities	-	-0.33	-0.97	-0.16	-	-
Financing Cash Flow	4.04	3.71	14.03	7.36	0.3	-

Net Cash Flow

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Foreign Exchange Rate Adjustments	-	-	-	-	-0.01	0.15
Net Cash Flow	-6.25	-5.16	-0.87	-4.87	-2.46	-20.6

Free Cash Flow

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	-10.29	-8.87	-14.9	-12.36	-15.93	-17.23
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-0.61	-0.54	-1.23	-1.30	-2.14	-2.81
Levered Free Cash Flow	-7	-5.73	-9.01	-7.4	-9.06	-4.57
Unlevered Free Cash Flow	-7	-5.73	-9.01	-7.4	-9.06	-4.57

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Change in Working Capital	-1.12	0.72	0.34	-1.28	0.18	-2.79

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 6, 2026

Data Sources Report a data error